Published • loading... • Updated
NICE Backs New Treatment Option for Chronic Heart Failure
Summary by nationalhealthexecutive.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The National Agency for Health Surveillance (Anvisa) approved a new therapeutic indication for finerenone, Bayer's medicine, expanding its use to patients with a specific type of heart failure. The decision represents an advance in the treatment of a condition that affects millions of people worldwide and that until then had limited options for therapy.The new authorization includes patients with heart failure and left ventricular ejection fract…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
